Open AccessComparison of ACC/AHA and ESC Guideline Recommendations Following Trial Evidence for Statin Use in Primary Prevention of Cardiovascular Disease
Author(s) -
Jelena Pavlović,
Philip Greenland,
Jaap W. Deckers,
Jasper J. Brugts,
Maryam Kavousi,
Klodian Dhana,
M. Arfan Ikram,
Albert Hofman,
Bruno H. Stricker,
Oscar H. Franco,
Maarten J.G. Leening
Publication year - 2016
Publication title -
jama cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.108
H-Index - 63
eISSN - 2380-6591
pISSN - 2380-6583
DOI - 10.1001/jamacardio.2016.1577
Subject(s) - medicine , guideline , statin , population , randomized controlled trial , incidence (geometry) , cohort , cohort study , clinical trial , physical therapy , environmental health , pathology , physics , optics
The American College of Cardiology/American Heart Association (ACC/AHA) and the European Society of Cardiology (ESC) guidelines both recommend lipid-lowering treatment for primary prevention based on global risk for cardiovascular disease (CVD). However, randomized clinical trials (RCTs) for statin use have included participants with specific risk-factor profiles.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom